Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)

• Published in: Breast cancer research and treatment 2023-10, Vol.201 (3), p.409-415
• Main Authors: Kobayashi, Kokoro, Masuda, Norikazu, Mizuno, Toshiro, Miura, Kayo, Tokuda, Yutaka, Yoshinami, Tetsuhiro, Kawaguchi, Hidetoshi, Ohtani, Shoichiro, Saeki, Toshiaki, Toi, Masakazu, Takeuchi, Masahiro, Ito, Yoshinori
• Format: Article
• Language: English
• Subjects: Anthracycline; Anthracyclines; Breast cancer; Breast Neoplasms - drug therapy; Cancer research; Clinical Trial; Clinical trials; ErbB-2 protein; Female; Hormones; Humans; Induction Chemotherapy; Induction therapy; Medical colleges; Medicine; Medicine & Public Health; Metastases; Metastasis; Oncology; Product development; Prospective Studies; Quality of Life; Survival
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-023-07030-x

Purpose Metastatic breast cancer (MBC) is usually incurable; treatment aims to maximize patients’ function and quality of life (QOL). Eribulin is a standard treatment in patients with MBC pretreated with anthracycline and taxane; however, the best administration schedule is unknown. Methods In this prospective phase II trial of patients with luminal MBC, we administered biweekly eribulin to patients who completed a three-cycle induction treatment. Results Sixty patients with hormone-receptor-positive and HER2-negative MBC were enrolled; 40 obtained stable disease (SD) or better efficacy after induction therapy, after which they were switched to biweekly maintenance administration. The median progression-free survival (PFS) in patients who switched to maintenance therapy was 15.21 weeks (95% CI 9.71–22.14), starting on the first day of maintenance therapy. Overall survival (OS) in patients who switched to maintenance therapy was 21.39 months (95% CI 18.89–32.89). PFS and OS in the whole population starting from the registration date were 19.00 weeks (95% CI 17.00–25.00) and 21.52 months (95% CI 16.23–24.25), respectively. PFS from the enrollment date for patients who received maintenance therapy was 25.29 weeks (95% CI 19.14–32.14). Patients who achieved complete response or partial response during induction therapy had significantly longer PFS compared to patients with SD. Conclusion The efficacy of biweekly administration of eribulin at maintenance was nonsignificant. However, less frequent visits are convenient, and reduced dose intensity improves safety. Biweekly administration, besides dose reduction, could be an acceptable option for patients who are unable to maintain a standard regimen.